A Compelling Case for King Pharma
We believe new management at King Pharmaceuticals (KG: $19) has done an admirable job so far in rectifying the company's past woes, defending its key franchises, and expanding the product portfolio. While King is expected to eventually face significant patent erosion on key products in the years ahead, we believe new product development projects, especially in the area of pain management, bode well for long-term growth. We also see future prospects enhanced by additional product acquisitions or in-licensing opportunities, which would be financed through ongoing strong cash flow and the company's over $900 million in cash.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.